<DOC>
	<DOC>NCT01981005</DOC>
	<brief_summary>This non-randomized, single group, open-label study will investigate the mass balance, routes of elimination, pharmacokinetics, and metabolism of a single oral dose of RO5424802 and the pharmacokinetics of a 14C-labeled tracer in healthy volunteers</brief_summary>
	<brief_title>A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802</brief_title>
	<detailed_description />
	<criteria>Male adults, 18 to 45 years of age, inclusive Body mass index (BMI) from 18 to 32 kg/m2, inclusive Willingness to use effective contraception as outlined in the protocol Willingness to abstain from alcohol and xanthinecontaining beverages or food (coffee, tea, cola, chocolate and "energy drinks") from 72 hours prior to the first dose until discharged Willingness to avoid prolonged sun exposure and guard against sunburn during study &amp; followup Clinically significant medical history or findings in physical examination, vital signs, or laboratory test results prior to study start Positive screening tests for hepatitis B or C, HIV, alcohol, drugs of abuse, or tobacco Regular smoking within 6 months prior to first dosing. Subjects should avoid smoky environments for at least 1 week prior to each cotinine screen Excessive alcohol consumption Use of any metabolic inducers (including herbals such as St. John's Wort) within 4 weeks or 5 halflives (whichever is longer) before the first dose of study medication, including but not limited to: rifampin, rifabutin, glucocorticoids, carbamazepine, phenytoin and phenobarbital Regular work with ionizing radiation or radioactive material Subjects enrolled in a previous radiolabel study or who have received radiotherapy within 12 months prior to first dosing such that total radioactivity over a 12 month period would exceed an acceptable radiation burden &gt; 0.1 mSv Exposure to radiation for diagnostic reasons (except dental Xrays and plain Xrays of thorax and bony skeleton [excluding spinal column]), during work or participation in a medical trial in the previous year Strenuous activity, sunbathing, or contact sports are not allowed from 4 days prior to entry into the clinical site until study followup Participation in an investigational drug or device study within 60 days (or 6 months for biologic therapies) prior to first dosing</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>